Active Low-Carber Forums
Atkins diet and low carb discussion provided free for information only, not as medical advice.
Home Plans Tips Recipes Tools Stories Studies Products
Active Low-Carber Forums
A sugar-free zone


Welcome to the Active Low-Carber Forums.
Support for Atkins diet, Protein Power, Neanderthin (Paleo Diet), CAD/CALP, Dr. Bernstein Diabetes Solution and any other healthy low-carb diet or plan, all are welcome in our lowcarb community. Forget starvation and fad diets -- join the healthy eating crowd! You may register by clicking here, it's free!

Go Back   Active Low-Carber Forums > Main Low-Carb Diets Forums & Support > Low-Carb Studies & Research / Media Watch > LC Research/Media
User Name
Password
FAQ Members Calendar Mark Forums Read Search Gallery My P.L.A.N. Survey


Reply
 
Thread Tools Display Modes
  #1   ^
Old Tue, Nov-07-00, 17:29
tamarian's Avatar
tamarian tamarian is offline
Forum Founder
Posts: 19,570
 
Plan: Atkins/PP/BFL
Stats: 400/223/200 Male 5 ft 11
BF:37%/17%/12%
Progress: 89%
Location: Ottawa, ON
Lightbulb

Tuesday November 7, 8:33 am Eastern Time
Press Release
Research Study Provides Strong Evidence That Colorectal Cancer is a Manifestation of Syndrome X
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Nov. 7, 2000--Shaman Pharmaceuticals, Inc. (OTC BB:SHPH.OB - news) today announced that there is new scientific evidence that colorectal cancer may be just one more, among a long list, of the life threatening manifestations emerging from the high insulin levels of Syndrome X.

Rudolf Kaaks, Ph.D. and colleagues of the International Agency for Research on Cancer, Lyon, France, in an article published in the Journal of the National Cancer Institute (Vol. 92, No. 19, October 4, 2000), presented strong evidence linking colorectal cancer with high insulin levels. In this study of 14,275 subjects, Kaaks and associates, using C-peptide as a marker to measure insulin secretion, showed that the higher the baseline C-peptide, the greater was the increase in risk of colorectal cancer in individuals with the highest insulin levels.

The Kaaks results are not the first ones pointing to insulin resistance and high insulin levels as predictors of cancer. Other published studies have presented evidence that high insulin levels both predict the development of several different kinds of cancer as well as their progression. Given this data, it may be that an important way to decrease risk of cancer is to maintain low insulin levels and to generally follow treatment for Syndrome X.

``Assuming that the link between elevated insulin levels and cancer continues,'' said Gerald Reaven, M.D., Professor Active Emeritus at Stanford University and Shaman Senior Vice President of Clinical Affairs, ``efforts to maintain insulin sensitivity and low insulin levels might well be helpful in lowering risk of certain kinds of cancer. Obviously, no intervention studies have been done yet to show that lowering insulin levels reduces the threat of cancer. However, until the results of such studies are available it seems prudent to follow lifestyle behaviors that will keep insulin levels as low as possible.''

Research studies over the past 35 years have accumulated powerful evidence showing that Syndrome X affects approximately one out of every three individuals in the general population-about 75 million Americans, and that it triggers half, and probably more, of all heart attacks. Syndrome X also has the negative distinction of leading to type 2 diabetes mellitus, which has erupted in epidemic proportions in American adolescents.

Syndrome X was first described in 1988 by Dr. Reaven, author of Syndrome X, The Silent Killer That Can Give You A Heart Attack, (Simon & Schuster). Shaman has developed its new Syn X Bar which is the company's first Syndrome X product on the market, in a line of dietary supplements designed to mitigate the major risk factors for coronary heart disease and other associated manifestations. The Syn X Bar contains the careful balance of 15% protein, 40% fat (mostly monounsaturated), and 45% carbohydrate. This ratio has been clinically proven to help maintain healthy insulin levels and reduce the major risk factors for heart disease and help attenuate the development of type 2 diabetes. Dr. Reaven's diet also addresses maintaining healthy LDL cholesterol, a risk factor for coronary heart disease that is unassociated with Syndrome X.

``Syndrome X'', said Dr. Reaven, ``not only can have a bad impact on nearly one-third of all Americans in terms of heart disease, and most likely cancer as well, it can also lead to polycystic ovary syndrome which can cause separate problems in women. Among those problems in this group of women are elevated testosterone levels, the development of masculine physical traits and difficulty conceiving. It's tragic because in most cases the problems can be controlled or eliminated with the Syndrome X Diet, weight loss and physical activity programs.''

Shaman has retained Roth Capital Inc., an investment bank that focuses on emerging growth and middle market companies, to provide a broad range of corporate finance, research, syndicate sales and trading services to assist Shaman in exploring strategic business opportunities to drive shareholder value. One of the assets Roth Capital will work with, among many others, is the Syn X line of products for lowering triglyceride levels, weight loss and promoting general cardiovascular health.

For more information about Syndrome X, what it is and who has it visit http://www.syndromexweb.com.

Shaman Pharmaceuticals, Inc. is a leader in medicinal plant research and commercialization of proprietary dietary supplements. Shaman works collaboratively with indigenous communities to discover, harvest and reforest medicinal plants. The Company also provides cultural educational programs in conjunction with rainforest communities.

This press release contains, among other things, certain statements of a forward-looking nature relating to Shaman's ability to advance its development and research programs. Such statements involve a number of risk and uncertainties including the Risk Factors listed in the Shaman Pharmaceuticals, Inc.'s Annual Report on Form 10K and 10K/A for the year ended December 31, 1999. These filings are available upon request at 650/952-7070. Also visit Shaman at http://www.Shaman.com.

http://biz.yahoo.com/bw/001107/ca_shaman_.html
Reply With Quote
Sponsored Links
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

vB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Similar Threads
Thread Thread Starter Forum Replies Last Post
"Truth about the cancer trap" gotbeer LC Research/Media 0 Tue, Jan-20-04 14:03
Red Meat Increases Risk of Colorectal Cancer doreen T LC Research/Media 1 Tue, Nov-19-02 17:44
Diet Rich in Soy Protein Lowers Estrogens Associated with Breast Cancer tamarian LC Research/Media 8 Wed, Sep-25-02 17:23
Exercise Builds a Reputation Against Cancer fern2340 Beginner/Low Intensity 0 Wed, Dec-26-01 08:58


All times are GMT -6. The time now is 15:28.


Copyright © 2000-2024 Active Low-Carber Forums @ forum.lowcarber.org
Powered by: vBulletin, Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.